<\/p>\n\n\n\n
Estos nuevos tipos de c\u00e1ncer se han observado en mujeres con implantes texturizados o lisos con relleno de soluci\u00f3n salina o silic\u00f3n. Estos tipos de c\u00e1ncer son de manifestaci\u00f3n extremadamente rara. La FDA ha reportado casos de un tipo de c\u00e1ncer de piel y de sangre en las cicatrices que se forman en las \u00e1reas cercanas a los implantes de seno. Estos linfomas recientemente reportados son diferentes al linfoma anapl\u00e1sico de c\u00e9lulas grandes asociado a implantes mamarios (LACG-IM) que se report\u00f3 anteriormente. (Publicado el 27\/09\/2022)<\/p>\n\n\n\n
This update is about the new release of security issued by the FDA about the types of cancer of rare manifestation that is presented in the scars that are formed around breast implants.<\/p>\n\n\n\n
For years, the FDA has received reports of damaging events associated with breast implants. The people who make the decision to undergo surgery, reconstruction or breast augmentation should be aware of the risks associated with these implants. The medical staff must also be aware of these risks to provide adequate information to people who are considering implants, and monitor patients who are already placed.<\/p>\n\n\n\n
Previously, the FDA reported a possible link between the implants and lymphoma rare manifestation called anaplastic large cell lymphoma (ALCL-IM) and the disease-filled breast implants (BII, for its acronym in English). For more information on this topic, refer to the publications and information XRAY here<\/a>. From these results, the FDA has monitored more closely the possible side effects associated with breast implants.<\/p>\n\n\n\n This update reports on a type of skin cancer is very rare called squamous cell carcinoma associated with breast implants (CCE-IM) and on the types of cancer of the immune system called lymphomas whose manifestation has been reported in the scars that form a capsule around the breast implants.<\/p>\n\n\n\n Squamous cell carcinoma (SCC) is the second type of skin cancer is more frequent. The CCE is most often found in the parts of the body exposed to the sun. Although it is very rare, it is known that the CCE can form scars. The CCE-IM is developed in the capsule of the scars that are formed around breast implants. The treatment against the CCE-IM involves surgery to remove the implant and the capsule surrounding it.<\/p>\n\n\n\n For August 2022, in the medical literature had reported 16 cases of people with CCE-IM. September 1, 2022, the FDA had received 10 reports of breast implants associated with CCE-IM.<\/p>\n\n\n\n Lymphoma is a cancer that starts in the cells that fight infections of the immune system called lymphocytes. There are many types of lymphomas.<\/p>\n\n\n\n Scientists are still without a full understanding of the causes of lymphoma. However, people infected with HIV, Epstein-Barr virus or other viruses, which have been exposed to high levels of ionizing radiation, have a family history of lymphoma or who have been exposed to high levels of pesticides, herbicides or other chemicals are at a higher risk of developing lymphoma.<\/p>\n\n\n\n The treatment varies depending on the type of lymphoma. Treatments may include chemotherapy, radiation therapy, targeted or immunotherapy.<\/p>\n\n\n\n The symptoms of the CCE-IM and lymphoma in the sites of breast implants can include any of the following:<\/p>\n\n\n\n In a normal year, about 400,000 women undergo surgery for breast implants in the united States. Of that amount, approximately 300,000 undergo this surgery for cosmetic reasons and approximately 100,000 are placed implants for reconstruction surgery after a mastectomy to prevent or treat breast cancer. Currently, it is estimated that 6.5 million people in the united States have breast implants.<\/p>\n\n\n\n In very few cases have been reported manifestation of CCE-IM and lymphoma (different from the ALCL-IM) in the literature or to the FDA and the information in the risk calculation is not available.<\/p>\n\n\n\n It is important to know that cases of CCE-IM and lymphomas associated with breast implants are very rare. Approximately 1 person out of 217,000 with breast implants can be diagnosed with CCE-IM, while approximately 1 person 162,500 may be diagnosed with lymphoma. It is equally important to note that it is not clear if these rare types of cancer are caused by breast implants, or are matches.<\/p>\n\n\n\n In response to the information collected by the FDA regarding breast implants, the agency issued a safety alert for the presence of CCE-IM and lymphoma in the scarring around the breast implants. This is not to say that people with breast implants need to be removed. The FDA does not recommend that you perform the surgery to remove the breast implants, unless the person presents with symptoms related to the cancer. <\/p>\n\n\n\n The majority of women with breast implants are happy with the results. However, the breast implants are associated with known risks. Very few people have reported the presence of CCE-IM or lymphoma in the capsule of the scarring around the implant.<\/p>\n\n\n\n These new cancers have been seen in women with textured or smooth implants filled with saline or silicone. These cancers are extremely rare. The FDA has reported cases of a type of skin and blood cancer in the scars that form in the areas near breast implants. These newly reported lymphomas are different from the previously reported breast implant-associated anaplastic large cell lymphoma (ALCL-IM). (Posted 09\/27\/2022)<\/p>\n\n\n\n This update is about the new safety communication issued by the FDA regarding rare cancers that occur in the scars that form around breast implants.<\/p>\n\n\n\n For years, the FDA has received reports of harmful events associated with breast implants. People who make the decision to undergo breast augmentation or reconstruction surgery should be informed of the risks associated with these implants. Medical personnel should also be aware of these risks in order to provide adequate information to people who are considering implants and to monitor patients who have already had them.<\/p>\n\n\n\nWhat is CCE-IM?<\/h2>\n\n\n\n
What is lymphoma?<\/h2>\n\n\n\n
What is the treatment for lymphoma?<\/h2>\n\n\n\n
How do you detect these types of cancer?<\/h2>\n\n\n\n
\n
How often gives the appearance of CCE-IM or lymphoma in the capsule around the implant?<\/h2>\n\n\n\n
<\/th> CCE-IM<\/th> Linforma<\/th> ALCL-IM<\/th><\/tr><\/thead> Cases to date<\/td> 16 in the literature; 2 reported to the American Society of Plastic Surgeons; 10 reports on breast implants to the FDA<\/td> 30 cases in the literature; 12 reports on breast implants to the FDA<\/td> 400 cases in the united States (1,227 at the global level)<\/td><\/tr> Frequency<\/td> 28 (6.5 million in EE. UU.)<\/td> 42 (6.5 million in EE. UU.)<\/td> 400 (from 6.5 million in EE. UU.)<\/td><\/tr> Risks<\/td> Unknown<\/td> Unknown<\/td> 1:2,207-1:86,029* * * * * Varies by the type of implant<\/td><\/tr> Average time elapsed from the first surgery when implants<\/td> Approximately 20 years<\/td> Approximately 20 years<\/td> Approximately 10 years<\/td><\/tr> Implant surface<\/td> Smooth or textured<\/td> Smooth or textured<\/td> Textured<\/td><\/tr> Type of implant<\/td> Stuffed with saline or silicone<\/td> Stuffed with saline or silicone<\/td> Stuffed with saline or silicone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Context<\/h2>\n\n\n\n
Conclusions<\/h2>\n\n\n\n
\n\n\n\nWhat Is This Update About?<\/h2>\n\n\n\n
Why Is This Update Important?<\/h2>\n\n\n\n